SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Parke, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parke, A. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Antimalarial Drugs, Pregnancy and Lactation

Ann L. Parke

University of Connecticut Health Center, Department of Medicine, Division of Rheumatic Diseases, 263 Farmington Avenue, Farmington, CT 06030-1310, USA

Disease activity has been demonstrated to be one of the major factors contributing to fetal loss in SLE patients, and discontinuation of antimalarial therapy can precipitate a flare of disease. It is therefore important to determine whether it is safe to continue antimalarial therapy throughout pregnancy. We have previously stated that we consider lupus patients and their fetuses to be at risk for disaster if antimalarial therapy is discontinued during pregnancy, and it has been our experience that lupus patients can produce normal offspring even if they are taking daily chloroquine or hydroxychloroquine. Several other reports now support our findings that it is probably safe to continue antimalarial therapy during pregnancy, although there are no large studies published. Data on the secretion of hydroxychloroquine in the breast milk of patients on steady-state hydroxychloroquine therapy are minimal, and further studies are required to determine whether these women can safely nurse their infants while taking hydroxychloroquine daily.

Key Words: Chloroquine • Hydroxychloroquine • Pregnancy • Systemic lupus erythematosus • Lactation

Lupus, Vol. 2, No. 1 suppl, S21-S23 (1993)
DOI: 10.1177/096120339300200106


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
LupusHome page
M. Khamashta, N. Buchanan, and G. Hughes
The use of hydroxychloroquine in lupus pregnancy : the British experience
Lupus, June 1, 1996; 5(1_suppl): S65 - S66.
[Abstract] [PDF]


Home page
LupusHome page
J. Martinez-Rueda, C. Arce-Salinas, A. Kraus, J. Alcocer-Varela, and D. Alarcon-Segovia
Factors associated with fetal losses in severe systemic lupus erythematosus
Lupus, April 1, 1996; 5(2): 113 - 119.
[Abstract] [PDF]



Advertisement